Treating cancer is a major health priority in western society. Coupled with attempts to alter unhealthy behaviour, it is hoped that better cancer treatment can reduce premature deaths.
Anti-APE1 mouse monoclonal antibodies from Novus Biologicals were antibodies used to investigate drug resistance in non-small cell lung carcinoma (Wang et al., Lung Cancer 2009, 65(3), pp. 298-304). Tumour drug resistance results in less successful chemotherapy.